PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
REGULATORY
Japan Diet Enacts Bill to Create “Japan CDC”
The Japanese Diet on May 31 passed into law a bill to integrate two national centers into a so-called Japanese version of the US Centers for Disease Control and Prevention (CDC). The law will come into effect within three years…
To read the full story
Related Article
- NCGM President to Take Helm of Japan CDC after April Merger
August 29, 2024
- MHLW Holds 1st Meeting to Consider Structure of Japan CDC
January 26, 2024
- MHLW Preparatory Council Boots Up for Japan-Version of CDC
October 13, 2023
- Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
June 22, 2023
- Japan Cabinet Approves Bill to Create “Japan CDC”
March 8, 2023
- MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
January 13, 2023
REGULATORY
- MHLW to Discuss Faster MCM Approvals during Health Emergencies
October 26, 2026
- Foreign Price Adjustment Rule a Key Issue in Japan’s MFN Response: Official
October 26, 2026
- MHLW Official Vows Crackdown on Illegal Mounjaro Sales
October 26, 2026
- Temodal, Topotecin Gain NHI Coverage for Neuroblastoma Combo Therapy
October 26, 2026
- Japan Approves OTC Version of Taiho’s Allergy Drug Bilanoa
October 26, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…